Purchasing agent of Iressa in India, purchasing Iressa in India, price of Iressa in India

/ ' ' (【Drug name】
/ ' ' Iressa
/ ' ' ( (Common name
Gefitinib tablets< br/> / ' ' ( ( English name

/ ' ' ( ([Character]
Brown, oval, biconvex, film-coated tablet with printed on one side and printed on the other side. Each tablet Contains gefitinib.
/ ' ' ( [Pharmacology and Toxicology]
/ ' ' ( (, Pharmacokinetic properties
(
Gefitinib is an option Epidermal growth factor receptor tyrosine kinase inhibitor. This enzyme is usually expressed in solid tumors of epithelial origin. Inhibition of tyrosine kinase activity can hinder tumor growth, metastasis and angiogenesis, and increase tumor cell apoptosis. . In vivo, gefitinib extensively inhibits the tumor growth of human tumor cell-derived lines xenografted in nude mice, and improves the anti-tumor activity of chemotherapy, radiotherapy, and hormone therapy. In clinical experiments, gefitinib has been confirmed to have an effect on local Advanced or metastatic non-small cell lung cancer has an objective anti-tumor response and can improve disease-related symptoms.
/ ' ' ( (, Pharmacokinetic properties
(
After intravenous administration , gefitinib is rapidly cleared and widely distributed, with an average clearance half-life of hours. After oral administration in cancer patients, absorption is slow, with an average terminal half-life of hours. Gefitinib accumulates twice as many times a day after daily administration. After oral administration, a steady state is reached. When administered at hourly intervals, the circulating plasma drug concentration is generally maintained at between times.
/ ' ' ( ( (, absorption
(
After oral administration, gefitinib The peak plasma concentration of gefitinib occurred at to hours after dosing. The average absorption bioavailability in cancer patients was %. The effect of food on the absorption of gefitinib was not obvious. In an experiment with healthy volunteers, when the value was maintained at Above, the absorption of gefitinib is reduced by % (see sections . and .).